The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 10, Pages 2805
Publisher
MDPI AG
Online
2020-09-30
DOI
10.3390/cancers12102805
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- Epithelial ovarian cancer risk: A review of the current genetic landscape
- (2019) Nicola Flaum et al. CLINICAL GENETICS
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
- (2019) N Colombo et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Germline BRCA-associated Endometrial Carcinoma is a Distinct Clinicopathologic Entity.
- (2019) Marthe M de Jonge et al. CLINICAL CANCER RESEARCH
- Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
- (2019) Johan Staaf et al. NATURE MEDICINE
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue
- (2018) Marthe M. de Jonge et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Spatiotemporal dynamics of homologous recombination repair at single collapsed replication forks
- (2018) Donna R. Whelan et al. Nature Communications
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
- (2018) Marthe M. de Jonge et al. CLINICAL CANCER RESEARCH
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- RECIST 1.1—Update and clarification: From the RECIST committee
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- TP53 mutations in epithelial ovarian cancer
- (2016) Yu Zhang et al. Translational Cancer Research
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
- (2014) M J Patterson et al. BRITISH JOURNAL OF CANCER
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
- (2014) I. Ruscito et al. EUROPEAN JOURNAL OF CANCER
- An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
- (2014) Monjri M. Shah et al. GYNECOLOGIC ONCOLOGY
- Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer
- (2014) Jianping Lu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Integrated analysis of germline and somatic variants in ovarian cancer
- (2014) Krishna L. Kanchi et al. Nature Communications
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum
- (2013) Jaime Prat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
- (2012) A. Mukhopadhyay et al. CANCER RESEARCH
- Erratum: Integrated genomic analyses of ovarian carcinoma
- (2012) The Cancer Genome Atlas Research Network NATURE
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- (2012) Jonathan Ledermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
- (2011) T. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
- (2010) Gordon JS Rustin et al. LANCET
- Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
- (2009) H. Willers et al. MOLECULAR CANCER RESEARCH
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results
- (2008) Sharon E. Plon et al. HUMAN MUTATION
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started